{"entity":{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","aka":[],"tldr":"Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer.","summary":"Domenica Lorusso was principal investigator of KEYNOTE-A18, the ENGOT trial showing pembrolizumab with chemoradiotherapy improves progression-free and overall survival in high-risk locally advanced cervical cancer, the first systemic addition to chemoradiation to do so in two decades. She has led the MITO group's ovarian and endometrial trials and co-led studies of trastuzumab deruxtecan in gynaecological cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lorusso%20D%5BAuthor%5D%20cervical%20pembrolizumab"}],"tags":["cervical","immunotherapy","italy"],"related":[],"cancers":["cervical","endometrial","ovarian"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab","trastuzumab-deruxtecan"],"companies":[],"institutions":["humanitas"],"pathways":[],"terms":[],"trials":["keynote-a18"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-a18-pfs-lancet-2024","paper-keynote-a18-os-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Gynaecological Oncology, Humanitas San Pio X and Humanitas University, Milan","institutionId":"humanitas","specialisms":["Cervical cancer","Endometrial cancer","Ovarian cancer","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lorusso%20D%5BAuthor%5D%20cervical%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00317-9"},{"title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)01808-7"}],"orcid":"0000-0003-0981-0598"},"route":"/people/domenica-lorusso/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/"}],"trial":[{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/"}],"paper":[{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/"},{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/"}]}}